Functional dyspepsia. Functional dyspepsia,Mirtazapine,Buspirone,Anxiety
Conditions
Interventions
Intervention 1: Intervention group: First - Buspirone receiving group with a dose of 5 mg three times a day for three months (Buspirax-brand name, Tehrandaroo factory). Intervention 2: Control group:
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Willingness to participate in the study after explaining all the objectives of the research and the advantages and disadvantages of the methods Failure to receive psychological treatment before entering the study Lack of other structural or functional gastrointestinal disorders No other organic disease Possibility to keep the type and amount of drug used during the research period if the drug is used No alcohol and drugs No psychotic disorder and personality disorder Absence of alarm signs such as gastrointestinal bleeding, blood in the stool, fever, weight loss, anemia, nocturnal diarrhea, severe heartburn Age between 18 and 50 years
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of dyspepsia symptoms in the three groups receiving buspirone, mirtazapine and the control group. Timepoint: The severity of dyspepsia symptoms in the three groups receiving buspirone, mirtazapine before the intervention and one month after the intervention and three months after the intervention and in the control group before the intervention and one month after the intervention. Method of measurement: patient assessment of upper gastrointestinal symptom severity index questionnaire(pagi-sym).;Beck anxiety score in three groups receiving buspirone, mirtazapine and control group. Timepoint: Determining and comparing the mean score of Beck anxiety in the two groups receiving buspirone, receiving mirtazapine before the intervention, one month after the intervention and three months after the intervention and in the control group before the intervention and one month after the intervention. Method of measurement: Beck Anxiety Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Tahmineh Tavakoli
Birjand University of Medical Sciences
Outcome results
None listed